COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as sales growth slows, but investors cheered a better-than-expected Medicare pricing deal that helped lift the shares after an initial slide.

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from U.S. pharma giant Pfizer. On Monday, Pfizer said it had filed a second lawsuit against Novo and Metsera, arguing that Novo's bid for the smaller company was anticompetitive.

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a tense takeover battle with Pfizer.

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO Albert Bourla was limited in what he could say.But he said Pfizer was the best fit for Metsera.

Pfizer has launched a second lawsuit against Novo Nordisk over its $9 billion bid for biotech company Metsera. Pfizer accuses Novo of trying to stall the acquisition to suppress competition in the obesity drug market.